南予医学雑誌 第18巻
61/91
南予医誌 Vol.18 No. 1 2017-60-4) Shoffski P, Chawla S, Maki RG et al:Eribulin versus dacarbazine in previ-ously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387: 1629-1637, 20165) Park IH, Kwon Y, Kim EA et al: Major response to Pazopanib in metastatic malignant phyllodes tumor of breast.Invest New Drugs. 27(4): 387-388,20096) van der Graaf WT, Blay JY, Chawla SP et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma(PALETTE): a randomised, double-blind,placebo-controlled phase 3 trial. Lancet 379: 1879-86, 20127) Nakamura T, Matsumine A, Kawai A et al: The clinical outcome of Pa-zopanib treatment in japan patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group(JMOG)study. Cancer 122(9): 1408-1416, 20168) Kasper B, Sleifer S, Litiere S et al:Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two Euro-pean Organization for Research and Treatment of Cancer(RORTC)clini-cal trials 62043 and 62072. Annals of Oncol 25: 719-724, 2014
元のページ
../index.html#61